Product Description
Mechanisms of Action: EP2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Glaucoma|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01291108 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2011-10-01 |
2019-03-19 |
||
| NCT01001195 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2010-04-01 |
2019-03-19 |
Treatments |
|
| NCT00809848 | P2 |
Completed |
Hypertension|Glaucoma |
2009-05-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|